Platelet x CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer

被引：22

作者：

Miyamoto, Ryoichi ^{[1
]}

Oda, Tatsuya ^{[1
]}

Hashimoto, Shinji ^{[1
]}

Kurokawa, Tomohiro ^{[1
]}

Kohno, Keisuke ^{[1
]}

Akashi, Yoshimasa ^{[1
]}

Ohara, Yusuke ^{[1
]}

Yamada, Keiichi ^{[1
]}

Enomoto, Tsuyoshi ^{[1
]}

Ohkohchi, Nobuhiro ^{[1
]}

机构：

[1] Univ Tsukuba, Dept Surg, Div Gastroenterol & Hepatobiliary Surg & Organ Tr, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan

来源：

PANCREAS | 2017年 / 46卷 / 01期

基金：

日本学术振兴会;

关键词：

thrombocytosis; pancreatic cancer; platelet; CRP; inflammatory response; prognostic factor; DUCTAL ADENOCARCINOMA; VENOUS THROMBOEMBOLISM; CURATIVE RESECTION; RECTAL-CANCER; FREE SURVIVAL; THROMBOCYTOSIS; COUNTS; TRIAL; RISK; GEMCITABINE;

D O I：

10.1097/MPA.0000000000000697

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objective: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. Methods: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. Results: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet x CRP multiplier value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). Conclusions: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet x CRP multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.

引用

页码：35 / 41

页数：7